Thus, COVID-19 may also represent a form of secondary thrombotic microangiopathy [106], and mild loss of ADAMTS13 is more likely than is acquired TTP [104] in COVID-19. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.